SAM #NOI-FDA-134639

FDA Seeks Photothermal mIRageLS System Upgrade for Microplastics Detection

The U.S. Food and Drug Administration (FDA) Human Foods Program is seeking to upgrade its existing mIRageLS Optical-Photothermal Infrared-Raman-Fluorescence (O-PTIR-R-FL) Microscope for advanced microplastics and nanoplastics detection in human foods. - Government Buyer: - U.S. Food and Drug Administration (FDA) - Human Foods Program, Office of Laboratory Operations and Applied Sciences, Office of Chemistry and Toxicology, Division of Analytical Chemistry, Spectroscopy and Mass Spectrometry Branch - Office of Acquisitions and Grants Services, CDER Acquisition Branch - OEM and Vendor: - Photothermal Spectroscopy Corp (PSC) is the sole OEM and patent holder for the O-PTIR technology - Products/Services Requested: - Counter-propagating configuration upgrade for the mIRageLS O-PTIR-R-FL Microscope - Includes optical components, quantum cascade laser-based IR illumination, transmission detection, and software integration for counter-propagating mode - Enables sub-500 nm spatial resolution for detection of microplastics and nanoplastics - Unique Requirements: - Upgrade must be fully compatible with the existing Photothermal mIRageLS system - Only PSC can provide the patented O-PTIR technology and required integration - Seamless operation and communication through existing system software - Estimated contract value is above $25,000 but below the Simplified Acquisition Threshold

Description

Pursuant to RFO 5.101(c)(4)(vii), the following identifies the intended source and explains why competition is not practicable for this requirement. 

Intended Contractor: 

Photothermal Spectroscopy Corp. 

325 Chapala St Santa Barbara, CA 93101 

CAGE Code: 83PQ8 

The basis for limiting this solicitation to a single source is that only one source is reasonably available, consistent with RFO 13.101(b) and the single-source standard at RFO 12.201-1(c).

Photothermal Spectroscopy Corp “PSC” is the one and only supplier that can meet the performance requirements outlined in the Statement of Work. The counter-propagating mode upgrade must be 100% compatible with the existing Photothermal mIRageLS to provide a seamless integration and establish full system communication and control through the single, existing software currently at FDA. PSC owns the patent for intellectual property protecting the O-PTIR technology and its associated capabilities. O-PTIR is protected by multiple patents and is exclusively available from Photothermal Spectroscopy. PSC will be the only provider to support the FDA in this requirement of the necessary parts and knowledgeable installation team to ensure 100% compatibility of the upgrade with the current FDA instrument. Photothermal is a US company and is a registered small business. A Brand Name acquisition is recommended, since only one provider meets the requirements for the acquisition.  

A written single-source justification has been prepared and approved in accordance with RFO 12.201-1(c) and RFO 13.101(b).

View original listing